CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.
Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In thi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3951414?pdf=render |
| _version_ | 1819152992423641088 |
|---|---|
| author | Tian Gao Yong Han Ling Yu Sheng Ao Ziyu Li Jiafu Ji |
| author_facet | Tian Gao Yong Han Ling Yu Sheng Ao Ziyu Li Jiafu Ji |
| author_sort | Tian Gao |
| collection | DOAJ |
| description | Identification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNA2 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNA2 was closely associated with tamoxifen resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, though CCNA2-Drug interaction network, we demonstrated the interactions between CCNA2 and several available cancer drugs. Overall, we suggest that CCNA2 is a biomarker for the prognosis of ER+ breast cancer and monitoring of tamoxifen efficacy. It's also a promising target for developing new strategies to prevent or even reverse tamoxifen resistance. Moreover, CCNA2 expression may help monitoring tamoxifen efficacy and directing personalized therapies. Nevertheless, in vivo and in vitro experiments and multi-center randomized controlled clinical trials are still needed before its application in clinical settings. |
| first_indexed | 2024-12-22T14:58:06Z |
| format | Article |
| id | doaj.art-d64381a6e5f844699471c78add98dcdc |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T14:58:06Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d64381a6e5f844699471c78add98dcdc2022-12-21T18:22:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0193e9177110.1371/journal.pone.0091771CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance.Tian GaoYong HanLing YuSheng AoZiyu LiJiafu JiIdentification of effective prognostic biomarkers and targets are of crucial importance to the management of estrogen receptor positive (ER+) breast cancer. CCNA2 (also known as CyclinA2) belongs to the highly conserved cyclin family and is significantly overexpressed in various cancer types. In this study, we demonstrated that CCNA2 had significant predictive power in distant metastasis free survival, disease free survival, recurrence free survival and overall survival of ER+ breast cancer patients. We also found that CCNA2 was closely associated with tamoxifen resistance. In addition, gene set enrichment analysis (GSEA) revealed that its expression was positively associated with genes overexpressed in endocrine therapy resistant samples. Finally, though CCNA2-Drug interaction network, we demonstrated the interactions between CCNA2 and several available cancer drugs. Overall, we suggest that CCNA2 is a biomarker for the prognosis of ER+ breast cancer and monitoring of tamoxifen efficacy. It's also a promising target for developing new strategies to prevent or even reverse tamoxifen resistance. Moreover, CCNA2 expression may help monitoring tamoxifen efficacy and directing personalized therapies. Nevertheless, in vivo and in vitro experiments and multi-center randomized controlled clinical trials are still needed before its application in clinical settings.http://europepmc.org/articles/PMC3951414?pdf=render |
| spellingShingle | Tian Gao Yong Han Ling Yu Sheng Ao Ziyu Li Jiafu Ji CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. PLoS ONE |
| title | CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. |
| title_full | CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. |
| title_fullStr | CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. |
| title_full_unstemmed | CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. |
| title_short | CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance. |
| title_sort | ccna2 is a prognostic biomarker for er breast cancer and tamoxifen resistance |
| url | http://europepmc.org/articles/PMC3951414?pdf=render |
| work_keys_str_mv | AT tiangao ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance AT yonghan ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance AT lingyu ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance AT shengao ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance AT ziyuli ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance AT jiafuji ccna2isaprognosticbiomarkerforerbreastcancerandtamoxifenresistance |